Glioblastoma, the most common and deadliest form of brain cancer, presents a grim prognosis for patients, with an average survival time of just 12 to 15 months after diagnosis. Only 6.9% of patients survive beyond five years, making it one of the least survivable cancers. Beyond survival rates, glioblastoma patients endure severe symptoms, including headaches, seizures, cognitive and personality changes, and neurological impairments, all of which drastically impact their quality of life. Despite this urgent need, targeted treatments for glioblastoma remain unavailable.

Researchers, however, see potential in immunotherapy, a treatment that uses the immune system to target cancer cells. Immunotherapy could potentially revolutionize glioblastoma treatment by addressing this devastating disease more effectively.

Glioblastoma belongs to a group of brain tumors known as "gliomas" that originate in the brain and spinal cord. Classified as a grade 4 tumor by the World Health Organization, it is among the most aggressive forms of cancer. In the UK alone, around 3,200 new cases of glioblastoma are diagnosed each year, contributing to the 12,700 brain and central nervous system tumors reported annually. Globally, glioblastoma affects about 3.2 to 4.2 individuals per 100,000, leading to approximately 150,000 new cases worldwide each year.

Currently, immunotherapy is used to treat cancers like melanoma, breast, and lung cancer, as well as autoimmune diseases such as multiple sclerosis and rheumatoid arthritis, infectious diseases like HIV and hepatitis, and allergic conditions. For glioblastoma, however, immunotherapy represents a promising but complex option. Due to glioblastoma’s adaptive nature, the tumor often shows varied mutations in different brain regions, making it challenging to target. Still, researchers remain hopeful.

Recent studies demonstrate that immunotherapy can be safely administered through cerebrospinal fluid injections, and scientists are working on methods to deliver the treatment more directly and effectively into the tumor. However, funding constraints have historically limited brain cancer research, though recent initiatives are drawing researchers from other fields to tackle glioblastoma.

Click this link BSc Zoology course

As an immunotherapy researcher with over 20 years of experience, I have studied immune system modulation in cancer and chronic infections and explored how immune cell interactions affect brain function, particularly in Alzheimer's disease. Now, I am applying that expertise to glioblastoma research, investigating how to bypass barriers that prevent treatment from reaching the tumor. My research is part of a larger, global effort to develop targeted immunotherapies for glioblastoma.

While glioblastoma remains difficult to treat, immunotherapy offers a potential pathway to better outcomes. Currently, no clinically approved immunotherapies exist for glioblastoma patients, and not all cancers respond to immunotherapy. Side effects, such as organ inflammation, also need careful management to prevent complications like brain swelling. Furthermore, the method of drug delivery is essential. Less invasive options, such as injections into the arm or spinal cord, are preferable to brain surgery.

Despite these challenges, the rising interest and investment in immunotherapy bring new optimism. My colleagues and I continue to hope that more effective treatments for glioblastoma will soon be available.